Verona Pharma plc Verona Pharma Appoints Stifel As Nominated Adviser

 
TIDMVRP 
 
 
   LONDON, Sept. 01, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) 
(NASDAQ:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical 
company focused on developing and commercializing innovative therapies 
for respiratory diseases, is pleased to announce the appointment of 
Stifel Nicolaus Europe Limited as its Nominated Adviser and Sole Broker 
with immediate effect. 
 
   About Verona Pharma plc 
 
   Verona Pharma is a clinical-stage biopharmaceutical company focused on 
developing and commercializing innovative therapies for the treatment of 
respiratory diseases with significant unmet medical needs. 
 
   Verona Pharma's product candidate, RPL554, is a first-in-class, inhaled, 
dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as 
both a bronchodilator and an anti-inflammatory agent in a single 
compound. Verona Pharma is developing RPL554 for the treatment of 
chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF), 
and potentially asthma. 
 
   For further information, please contact: 
 
 
 
 
Verona Pharma plc                                  Tel: [phone] 
Jan-Anders Karlsson, Chief Executive Officer       [e-mail] 
 
Stifel Nicolaus Europe Limited (Nominated Adviser  Tel: [phone] 
 and UK Broker) 
Stewart Wallace / Jonathan Senior / Ben Maddison   [e-mail] 
 
ICR, Inc. (US Media and Investor Enquiries) 
Darcie Robinson                                    Tel: [phone] 
                                                   [e-mail] 
Stephanie Carrington                               Tel: [phone] 
                                                   Stephanie.Carrington@icrinc 
                                                   .com 
 
FTI Consulting (UK Media and Investor Enquiries)   Tel: [phone] 
Simon Conway / Stephanie Cuthbert /                veronapharma@fticonsulting. 
 Natalie Garland-Collins                           com 
 
 
 
   This announcement is distributed by Nasdaq Corporate Solutions on behalf 
of Nasdaq Corporate Solutions clients. 
 
   The issuer of this announcement warrants that they are solely 
responsible for the content, accuracy and originality of the information 
contained therein. 
 
   Source: Verona Pharma plc via Globenewswire 
 
 
  http://www.veronapharma.com/ 
 

(END) Dow Jones Newswires

September 01, 2017 02:00 ET (06:00 GMT)

Copyright (c) 2017 Dow Jones & Company, Inc.